Patents by Inventor Ioannis Papaioannou
Ioannis Papaioannou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150241Abstract: The present invention relates to a novel method for the production of an encapsulated system for the self-healing of cracks formed within the matrix of building materials, preferably cementitious materials, such as concrete, mortar or render. Further, the invention refers to a novel encapsulated system comprising a cement-based active core and a hydrated cement-based protective shell, and to the use of said encapsulated system for the self-healing of cementitious materials such as concrete or mortar.Type: ApplicationFiled: March 4, 2022Publication date: May 9, 2024Applicant: National Centre for Scientific Research DemokritosInventors: Ioannis Karatasios, Stamatoula Papaioannou, Maria Amenta, Dimitrios Gournis, Vassilios Kilikoglou
-
Patent number: 10494449Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals.Type: GrantFiled: November 22, 2017Date of Patent: December 3, 2019Assignee: Lipoxen Technologies LimitedInventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
-
Patent number: 10406209Abstract: Derivatives are synthesized of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.Type: GrantFiled: September 26, 2016Date of Patent: September 10, 2019Assignee: Lipoxen Technologies LimitedInventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Dale Howard Hreczuk-Hirst, Ioannis Papaioannou
-
Patent number: 10155045Abstract: Derivatives of PSAs are synthesized, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.Type: GrantFiled: December 19, 2015Date of Patent: December 18, 2018Assignee: Lipoxen Technologies LimitedInventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
-
Patent number: 10155046Abstract: Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.Type: GrantFiled: December 19, 2015Date of Patent: December 18, 2018Assignee: Lipoxen Technologies LimitedInventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
-
Publication number: 20180298114Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd 21 1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals.Type: ApplicationFiled: November 22, 2017Publication date: October 18, 2018Applicant: Lipoxen Technologies LimitedInventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
-
Patent number: 9920137Abstract: A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.Type: GrantFiled: July 5, 2015Date of Patent: March 20, 2018Assignee: LIPOXEN TECHNOLOGIES LIMITEDInventors: Dale Howard Hreczuk-Hirst, Sanjay Jain, Peter Laing, Gregory Gregoriadis, Ioannis Papaioannou
-
Patent number: 9828443Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatized therapeutic agents intended for use in humans and animals.Type: GrantFiled: October 27, 2015Date of Patent: November 28, 2017Assignee: LIPOXEN TECHNOLOGIES LIMITEDInventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
-
Patent number: 9790288Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals.Type: GrantFiled: October 27, 2015Date of Patent: October 17, 2017Assignee: LIPOXEN TECHNOLOGIES LIMITEDInventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
-
Publication number: 20170007706Abstract: Derivatives are synthesized of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.Type: ApplicationFiled: September 26, 2016Publication date: January 12, 2017Applicant: Lipoxen Technologies LimitedInventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Dale Howard Hreczuk-Hirst, Ioannis Papaioannou
-
Patent number: 9452224Abstract: Derivatives are synthesized of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.Type: GrantFiled: January 15, 2014Date of Patent: September 27, 2016Assignee: LIPOXEN TECHNOLOGIES LIMITEDInventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Dale Howard Hreczuk-Hirst, Ioannis Papaioannou
-
Publication number: 20160159936Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals.Type: ApplicationFiled: October 27, 2015Publication date: June 9, 2016Applicant: LIPOXEN TECHNOLOGIES LIMITEDInventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
-
Publication number: 20160159935Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals.Type: ApplicationFiled: October 27, 2015Publication date: June 9, 2016Applicant: LIPOXEN TECHNOLOGIES LIMITEDInventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
-
Publication number: 20160120993Abstract: Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.Type: ApplicationFiled: December 19, 2015Publication date: May 5, 2016Applicant: Lipoxen Technologies LimitedInventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
-
Publication number: 20160101186Abstract: Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.Type: ApplicationFiled: December 19, 2015Publication date: April 14, 2016Applicant: Lipoxen Technologies LimitedInventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
-
Patent number: 9216227Abstract: Derivatives of PSAs are synthesized, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.Type: GrantFiled: December 23, 2014Date of Patent: December 22, 2015Assignee: Lipoxen Technologies LimitedInventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
-
Publication number: 20150344591Abstract: An amine or hydrazide derivative of a sialic acid unit, e.g. in a polysaccharide, is reacted with a bifunctional reagent at least one of the functionalities of which is an ester of N-hydroxy succinimide, to form an amide or hydrazide product. The product has a useful functionality, which allows it to be conjugated, for instance to proteins, drugs, drug delivery systems or the like. The process is of particular utility for derivatising amine groups introduced in sialic acid terminal groups of polysialic acids.Type: ApplicationFiled: July 5, 2015Publication date: December 3, 2015Applicant: LIPOXEN TECHNOLOGIES LIMITEDInventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
-
Patent number: 9200052Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatized therapeutic agents intended for use in humans and animals.Type: GrantFiled: January 15, 2014Date of Patent: December 1, 2015Assignee: Lipoxen Technologies LimitedInventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
-
Publication number: 20150307633Abstract: A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.Type: ApplicationFiled: July 5, 2015Publication date: October 29, 2015Applicant: LIPOXEN TECHNOLOGIES LIMITEDInventors: Dale Howard Hreczuk-Hirst, Sanjay Jain, Peter Laing, Gregory Gregoriadis, Ioannis Papaioannou
-
Patent number: 9102714Abstract: A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.Type: GrantFiled: October 11, 2012Date of Patent: August 11, 2015Assignee: Lipoxen Technologies LimitedInventors: Dale Howard Hreczuk-Hirst, Sanjay Jain, Peter Laing, Gregory Gregoriadis, Ioannis Papaioannou